Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plasma-Derived miRNAs as Fluid Biomarkers to Differentiate Alzheimer's and Frontotemporal Dementia.

Current issues in molecular biology·2026

Same author

Neuroradiological patterns and prognostic implications in type I Alexander disease.

Molecular genetics and metabolism·2026

Same author

Diabetes, impaired fasting glucose, and cognitive trajectories: a multi-cohort study.

medRxiv : the preprint server for health sciences·2026

Same author

Longitudinal Lifestyle Profiles Influence Health Trajectories in Aging: Evidence from a Population-Based Sample.

Neuroepidemiology·2026

Same author

Development and characterization of 3D spinal cord organoids to advance the study of amyotrophic lateral sclerosis.

Molecular biomedicine·2026

Same author

Plasma hippuric acid as a marker of frailty influenced by dietary fruit and vegetable consumption: longitudinal analysis in Italian cohorts of older adults.

npj aging·2026

Search research articles

Related Experiment Video

Updated: Oct 18, 2025

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

COVID-19 patients and Dementia: Frontal cortex transcriptomic data.

Maria Garofalo^1,2, Stella Gagliardi¹, Susanna Zucca³

¹Genomic and post-Genomic Unit, IRCCS Mondino Foundation, Via Mondino, 2, Pavia 27100, Italy.

|October 4, 2021

Summary

RNA sequencing of the frontal cortex revealed eleven differentially expressed genes in individuals with both COVID-19 and dementia. These findings offer insights into the neurological impact of SARS-CoV-2 infection and dementia.

Keywords:

Brain Gene expression SARS-CoV-2 Transcriptomics

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

Related Experiment Videos

Last Updated: Oct 18, 2025

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

Area of Science:

Neuroscience
Genomics
Infectious Diseases

Background:

The association between SARS-CoV-2 infection and Nervous System (NS) manifestations is increasingly recognized.
Dementia affects cognitive functions and is a growing public health concern.

Purpose of the Study:

To investigate gene expression differences in the frontal cortex of individuals with COVID-19 and dementia compared to those with dementia alone.
To identify specific genes affected by the co-occurrence of SARS-CoV-2 infection and dementia.

Main Methods:

RNA sequencing was performed on frontal cortex samples from COVID-19 positive and negative individuals, with and without dementia.
Differential Expression analysis was conducted using transcript counts to identify significant gene expression changes.

Main Results:

Eleven protein-coding genes were found to be differentially expressed in individuals with both COVID-19 and dementia compared to dementia-only patients.
These results highlight specific molecular alterations in the brain associated with the combined conditions.

Conclusions:

The identified differentially expressed genes provide potential targets for understanding the neurological impact of COVID-19 in dementia patients.
The data can be integrated with further studies for comprehensive analysis of gene expression in neurological disorders and viral infections.